Loading...
Inventiva S.A.
0RNK.L•LSE
Healthcare
Medical - Pharmaceuticals
£3.84
£-0.12(-2.91%)

Financial performance has remained strong, with revenue growing from $15.42M in Q4 2022 to $2.73M in Q2 2024. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$52.25M in Q2 2024, holding a steady -1911% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$51.82M. Net income rose to -$49.03M, keeping EPS at -$0.94. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan